Merck looking for biologics and oncology opportunities
Merck's Head R&D Roger Perlmutter on Biotechnology and Cancer:
"Perlmutter plans to move Merck away from primary care medicines and put more emphasis on biotechnology drugs and cancer therapies, Alex Arfaei, an analyst with BMO Capital Markets Corp. who was at the dinner, said today in a note to clients. “R&D will be more focused in terms of therapeutic areas and products that the company will invest in.”
Merck is also looking to acquire experimental cancer treatments, Perlmutter told the group, though it hadn’t seen a large number of likely targets, Arfaei said.
The company has fewer on-market and experimental biotechnology drugs than almost any other major pharmaceutical company, said Anderson, who also attended the dinner. “It’s exposure to biologics is too low.”
Perlmutter also will look to speed up experimental products in vaccines and viral treatments, including the liver infection hepatitis C and HIV, the analysts said."